Jul 2015

kiadis

Sole Global Coordinator & Joint Bookrunner

€ 32.7 million

Initial Public Offering

Kiadis Pharma

Kiadis Pharma is a clinical stage biopharmaceutical company focused on cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders

Kiadis Pharma floated on Euronext Amsterdam and Euronext Brussels
Proceeds of the IPO will be used to advance the clinical development of the lead products
Kempen & Co acted as Sole Global Coordinator and Joint Bookrunner in the transaction